Noznesky Justin J
Known title: Chief Mktg & Strategy OfficerCIK: 0001666600
Associated companies
Transaction History
| ATRC | ▼ Sell | Open Market | 6,182 | $240K | 7/29/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 27,991 | $0 | 3/1/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 15,198 | $0 | 3/1/2026 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 15,586 | $487K | 3/1/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 5,166 | $193K | 11/26/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 3,000 | $109K | 9/12/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 19,359 | $0 | 3/1/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 6,579 | $0 | 3/1/2025 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 9,673 | $375K | 3/1/2025 | View on chart |
| ATRC | ▼ Sell | Gift | 585 | $0 | 12/11/2024 | View on chart |
| ATRC | ▼ Sell | Open Market | 1,500 | $36K | 5/1/2024 | View on chart |
| ATRC | ▼ Sell | Open Market | 1,500 | $46K | 4/1/2024 | View on chart |
| ATRC | ▼ Sell | Open Market | 1,500 | $55K | 3/12/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 19,294 | $0 | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 9,328 | $0 | 3/1/2024 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 8,856 | $321K | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 547 | $21K | 6/30/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 8,036 | $0 | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 16,104 | $0 | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 7,083 | $275K | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 585 | $20K | 12/30/2022 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 7,474 | $520K | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 6,825 | $0 | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 7,789 | $0 | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.